At the start of the COVID pandemic, doctors and scientists were on the hunt for successful treatments that could lessen the virus’s toll. By this point, quite a few promising candidates have emerged, many of which are already on the market to treat other illnesses. Now, another potential COVID treatment joins the list in the form of a widely available and extensively tested inhaler, traditionally used to treat asthma and chronic obstructive pulmonary disease (COPD). According to a new study by NIHR Oxford Biomedical Research Centre (BRC), which has yet to be peer-reviewed, the drug budesonide was found to reduce the risk of severe illness by 90 percent. . .
Observing a total of 146 subjects, the researchers gave half of the group a budesonide inhaler for twice-daily doses of 800 micrograms, and the other half a placebo for a period of 28 days. Those who took the treatment were not only 90 percent less likely to require urgent care, they also reportedly benefited from shorter lengths of fever, and fewer long-term symptoms.
“I am encouraged to see the reduction in persistent symptoms at 14 and 28 days after treatment with budesonide,” Mona Bafadhel, MD, a professor and respiratory consultant also working at the Oxford University Hospitals NHS Foundation Trust, shared on the University of Oxford website. “Persistent symptoms after the initial COVID-19 illness have emerged as a long-term problem. Any intervention which could address this would be a major step forward,” she added. (Read more from “Study: Inhaling This COVID Treatment Reduces Severe COVID Risk 90%” HERE)